-
-
-
-
-
-
-
Arvinas Reports Third Quarter 2025 Financial Results and Provides Corporate Update
-
-
-
-
-
-
-
Arvinas and Pfizer's Vepdegestrant Significantly Improves Progression-Free Survival for Patients with ESR1-Mutant, ER+/HER2- Advanced Breast Cancer
-
-
-
-
-
-
-
Arvinas, Inc. (ARVN) Tops Q4 EPS by 33c
-
-
-
-
-
-
-
Arvinas to Report Third Quarter 2024 Financial Results and Provide Corporate Update and Host Webcast on Wednesday, October 30, 2024
-
-
-
-
-
-
-
Arvinas Reports First Quarter 2024 Financial Results and Provides Corporate Update
-
-
-
-
-
-
-
Arvinas, Inc. (ARVN) Tops Q3 EPS by 40c
-
-
-
-
-
-
-
Arvinas and Pfizer Announce Upcoming Vepdegestrant (ARV-471) Poster Presentations at the 2023 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress
-
1,168,522 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

